24 results about "Malignant phenotype" patented technology

The application relates to the technical field of medicines, and discloses an application of homoharringtonine in the preparation of a medicine for treating small cell lung cancer, and further provides a medicine for treating small cell lung cancer and containing homoharringtonine. The application discloses an action mechanism of homoharringtonine, an active ingredient of traditional Chinese medicine, against SCLC, and discloses that the traditional Chinese medicine ingredient HHT inhibits a malignant phenotype by targeting tumor-specific glycosylation enzyme MGAT5, provides an innovative perspective of glyco-biology for the research of traditional Chinese medicine against tumors, provides an important scientific basis for the subsequent development and application of homoharringtonine, and provides a new medicine treatment approach for treating small cell lung cancer.

The invention relates to a mouse liver cancer cell P1-Hepa1-6 capable of simulating human liver cancer metabolism reprogramming characteristics and application thereof, and belongs to the technical field of biotechnology and medicine. The invention provides a mouse liver cancer cell P1-Hepa1-6 which is preserved in the China Center for Type Culture Collection on November 12, 2025, the preservation address is Wuhan University, Wuhan, China, and the preservation number is CCTCC NO: C202586. The invention further provides a preparation method of the mouse liver cancer cell P1-Hepa1-6. The mouse liver cancer cell P1-Hepa1-6 has the advantages that the mouse liver cancer cell P1-Hepa1-6 can be used for preparing the mouse liver cancer cell P1-Hepa1-6; the mouse liver cancer cell P1-Hepa1-6 has high malignant phenotype, can simulate human liver cancer metabolism reprogramming characteristics, is high in pertinence and good in repeatability, and has important application value and market prospect in the fields of liver cancer basic research, drug target discovery, preclinical efficacy evaluation and the like.

The invention discloses application of a lipid synthesis inhibitor in treatment of breast cancer. Researches prove that F.n colonization exists in breast cancer tissues, and the F.n can regulate and control lipid deposition related gene expression and lipid metabolism change of tumor-related macrophages, so that lipid deposition of the macrophages and proliferation, invasion and migration capabilities of tumor cells are promoted; after the lipid deposition inhibitor is added, the lipid metabolism disorder of the tumor-associated macrophages can be inhibited, the tumor malignant phenotype is finally inhibited, and the treatment of the breast cancer is realized. The invention provides a new potential therapeutic target and a new therapeutic drug for effective treatment of breast cancer.

This invention discloses a photothermal synergistic tumor stem cell inhibition system, its preparation method, and its applications. Addressing the current lack of effective treatments for large / unresectable GBM and its strongly immunosuppressive microenvironment, this invention constructs an injectable hydrogel platform (MIN-PPIC@iGel) integrating multiple key functions. This platform achieves a synergistic therapeutic model involving photothermal ablation for local tumor reduction, inhibition of residual GBM stem cells (GSCs), and activation of dendritic cells (DCs)-mediated anti-tumor immunity. Cellular experiments show that this invention can synergistically kill GL261 cells, significantly inhibit tumor stem cells and malignant phenotypes, induce significant ICD, and enhance DC maturation and activation effects. In a large-volume orthotopic GBM mouse model, a single intratumoral injection of MIN-PPIC@iGel combined with short-term near-infrared light irradiation doubled survival; further combination with antibody therapy unexpectedly achieved long-term tumor-free survival in 50% of mice, providing a new strategy for the local treatment of unresectable GBM.

The application discloses application of an HTRA1 inhibitor in preparation of a drug for treating pancreatitis-cancer transformation, and belongs to the technical field of medicines.The HTRA1 inhibitor is screened through a drug database, the HTRA1 inhibitor is used to treat a pancreatic cancer cell line and a mouse pancreatitis-cancer transformation in-vivo model, it is proved that the HTRA1 inhibitor Carfilzomib can inhibit the malignant phenotype of Panc1 cells in vitro, and can inhibit the transformation of a KC mouse stimulated by cerulean into a pancreatic ductal adenocarcinoma in vivo, and the application provides a basis for using the HTRA1 inhibitor as the drug for treating pancreatitis-cancer transformation.

The application discloses application of a small-molecule compound for inhibiting HNF4 alpha degradation in preparation of a liver cancer treatment drug. The structural general formula of the small-molecule compound for inhibiting HNF4 alpha degradation is shown in the following formula: the small-molecule compound for inhibiting HNF4 alpha degradation provided by the application can play the biological effects of correcting glycolipid metabolism disorder of the liver, reducing liver fibrosis and inhibiting malignant phenotypes of liver cancer, and is applied to clinical treatment of chronic liver diseases and liver cancer.

The invention relates to the technical field of biomedicine, in particular to application of RAB26 as a prognosis evaluation marker and a treatment target of osteosarcoma. System research finds that RAB26 has significant differential expression between osteosarcoma primary lesion and metastasis lesion, high expression of RAB26 is closely related to poor overall lifetime and event-free lifetime of patients, and RAB26 can be used as an effective biomarker for evaluating osteosarcoma development risk and prognosis state. The RAB26 quantitative detection scheme established by the invention can accurately reflect the real change of RAB26 in tumor tissues or related samples, and provides a reliable basis for risk stratification, disease monitoring and prognosis judgment of clinical patients. On the other hand, the invention clarifies that RAB26 activates autophagy by up-regulating PDCD6IP and inhibiting an mTOR signal channel for the first time, so that the invasion and migration capabilities of osteosarcoma cells are enhanced, and malignant phenotypes of the cells can be remarkably weakened by inhibiting and intervening RAB26.

The application discloses application of FH acetylation in diagnosis, staging, treatment and prognosis prediction of colorectal cancer (CRC). The application screens acetylated non-histone proteins and acetylation sites related to CRC in a systematic manner, and for the first time finds that FH K80 acetylation modification level regulates the malignant phenotype of CRC, the FH K80 acetylation modification level presents significant difference in CRC patients, and is related to prognosis, and a high acetylation state (FH K80Q) can inhibit the proliferation, migration and invasion of CRC cells. The application provides a new direction for diagnosis, prognosis prediction and effective treatment of CRC, and has a wide application prospect in clinic.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The invention discloses a shRNA (short hairpin Ribonucleic Acid) interference library for inhibiting expression of CT45A3, a vector and application of the shRNA interference library in anti-colon cancer drugs, and belongs to the technical field of gene drugs. The shRNA interference library comprises one or more of the sequences as shown in SEQ ID NO.1-3. The invention also discloses a method for preparing the shRNA interference library. The shRNA interference library or the expression vector thereof can efficiently and specifically down-regulate the expression level of CT45A3 in colorectal cancer cells, so that abnormal activation of a downstream cancer promoting signal channel mediated by the shRNA interference library or the expression vector is blocked, and the development of malignant phenotypes is remarkably inhibited. The shRNA interference library has potential clinical application value in targeted therapy of colorectal cancer.

The invention discloses application of a small molecule compound for inhibiting degradation of HNF4alpha in preparation of a medicine for treating liver cancer. The structural general formula of the small molecule compound for inhibiting the degradation of the HNF4alpha is shown in the specification, the small molecule compound for inhibiting degradation of the HNF4alpha can play the biological effects of correcting liver glycolipid metabolism disorder, relieving liver fibrosis and inhibiting liver cancer malignant phenotypes, and is applied to clinical treatment of chronic liver diseases and liver cancer.

This invention discloses the application of TBC1D8, a member of the TBC1 domain family, in the preparation of predictive biomarkers for prognosis and immunotherapy responsiveness in human colorectal cancer patients. This invention evaluated the correlation between TBC1D8 levels and clinical characteristics and its biological functions using next-generation sequencing results from the TCGA database and in vitro and in vivo experiments. The results showed that elevated TBC1D8 levels were associated with poor prognosis in colorectal cancer patients. Experimental studies also observed that TBC1D8 is associated with a hypoxic microenvironment and may participate in regulating the malignant phenotype of colorectal cancer cells and tumor cell stemness. Furthermore, TBC1D8 is closely related to the infiltration of immunosuppressive macrophages; experiments showed that knocking down TBC1D8 significantly inhibited the differentiation and infiltration of immunosuppressive macrophages. Therefore, TBC1D8 can serve as a prognostic biomarker for colorectal cancer patients and may also be a novel therapeutic target for human colorectal cancer.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

The invention provides application of novel burkholderia cepacia as a marker for tumor diagnosis, screening, prediction or prognosis. The invention provides a qualitative and quantitative detection method for detecting the Burkholderia cenocepacia bacteria in the glioma for the first time. On one hand, through co-culture with Burkholderia cenocepacia bacteria, the malignant phenotypic capabilities of proliferation, invasion and the like of glioma cells can be remarkably enhanced; more importantly, the abundance value of the 16S rRNA gene of the Burkholderia cenocepacia bacteria can be used as a molecular marker for prognosis evaluation of the glioma and a target spot for treatment of the glioma. A new thought is provided for diagnosis of glioma, and important clinical value is achieved.

The application discloses a HeLa cell three-dimensional culture model, a preparation method and application. HeLa cells are mixed with a collagen-sodium alginate composite hydrogel precursor solution to obtain a cell-precursor mixture, the cell-precursor mixture is mixed with a CaCl2 solution to obtain a mixed solution, and the mixed solution is placed in an incubator for standing culture for 10-60 min, so that the hydrogel is cross-linked and solidified to form a three-dimensional culture system; complete culture medium is further added for continuous culture, and a HeLa cell three-dimensional culture model is constructed. The HeLa cell three-dimensional culture model is constructed by using the hydrogel, defects existing in simulation of a tumor microenvironment by two-dimensional culture and an animal model are effectively solved, the body microenvironment can be better simulated, cells form regular three-dimensional cell spheroids, a malignant phenotype is maintained, the accuracy and repeatability of drug screening are improved, and a reliable technical platform is provided for cervical cancer mechanism research and anti-tumor drug screening.

The present application relates to the technical field of medicine, and provides application of Ben Dung decoction in preparation of medicine for treating ovarian cancer, wherein the Ben Dung decoction is prepared from licorice, Szechuan lovage rhizome, Chinese angelica, pinellia, radix scrophulariae, radix puerariae, radix paeoniae, ginger and root white bark of prunus mira koehne with a mass ratio of (1.5-2.5):(1.5-2.5):(1.5-2.5):(3-5):(1-3):(6-10):(1.5-2.5):(3-5):(4-7). The Ben Dung decoction can significantly affect the morphology and cycle of ovarian cancer ES-2 and OV-1063 cells, effectively inhibit the malignant phenotypes such as proliferation, migration, infiltration and cloning of the ovarian cancer ES-2 and OV-1063 cells, and inhibit the expression level of CA125 and CEA proteins in the ovarian cancer OV-1063 cells.

The invention belongs to the technical field of cell molecular biology, and particularly relates to a laryngeal squamous cell carcinoma molecular marker and a detection method and application thereof. In order to provide a new way for detecting and treating the laryngeal squamous cell carcinoma, the invention discloses the laryngeal squamous cell carcinoma molecular marker LINC LSAMP-AS1, the sequence of the laryngeal squamous cell carcinoma molecular marker is shown as SEQ ID NO: 1, and the laryngeal squamous cell carcinoma molecular marker LINC LSAMP-AS1 is applied to laryngeal squamous cell carcinoma detection and prognosis judgment; the invention discloses siRNA of a targeted laryngeal squamous cell carcinoma molecular marker, a sense strand and an antisense strand of the siRNA are respectively SEQ ID NO: 4 and SEQ ID NO: 5, the siRNA can knock down the expression level of LINC LSAMP-AS1 in laryngeal squamous cell carcinoma cells, and the siRNA is used for preparing RNA drugs for inhibiting malignant phenotypes of laryngeal squamous cell carcinoma cells.

The invention belongs to the technical field of biological medicines and microorganisms, and particularly relates to an alpha-PD-L1 targeted nano-drug based on a parabacteroides coumarini membrane vesicle and a preparation method and application thereof.The nano-drug is prepared by taking a natural membrane vesicle derived from parabacteroides coumarini as a carrier, connecting an alpha-PD-L1 antibody to the surface of the carrier by adopting a chemical covalent method, and preparing the alpha-PD-L1 targeted nano-drug based on the parabacteroides coumarini membrane vesicle. The functionalized nano drug P-MVs / alpha-PD-L1 is formed; wherein the membrane vesicle carrier is obtained from a bacterial culture supernatant by combining gradient centrifugation with ultracentrifugation; in-vitro experiments show that the nano-drug can effectively inhibit malignant phenotypes such as proliferation, migration and invasion of breast cancer cells; animal in-vivo experiments prove that the nano-drug can significantly inhibit tumor growth and shows good biological safety; in conclusion, the alpha-PD-L1 targeted nano-drug provided by the invention has the advantages of a natural carrier and an immune targeting function, and has a definite application value in the field of breast cancer treatment.

The application belongs to the technical field of biological medicine, and discloses application of a miRNA-5134-5p inhibitor in preparation of an anti-breast cancer drug, wherein the miRNA-5134-5p inhibitor can effectively inhibit the invasion and migration ability of breast cancer cells, and has a significant anti-breast cancer effect. The application further provides a nucleotide sequence of the miRNA-5134-5p inhibitor, a probe sequence for detecting the expression level of miRNA-5134-5p, an anti-breast cancer small molecule drug, and a kit for evaluating the malignancy degree of breast cancer. Experiments prove that the miRNA-5134-5p inhibitor can significantly inhibit the malignant phenotype of breast cancer cells, and has potential clinical application value. The application provides a new target and strategy for the treatment of breast cancer, and has important clinical development and application prospects.

This invention relates to the field of biotechnology, specifically to the FAM166A gene missense mutation molecular marker and its application in esophageal cancer risk assessment or prognosis. It was found that the expression level of FAM166A in esophageal cancer patient tissues was significantly higher than that in normal controls, and its expression level was positively correlated with the occurrence and development of esophageal cancer. In vitro cell function experiments confirmed that the FAM166A gene P84L missense mutant, compared with wild-type FAM166A, significantly enhanced the proliferation, invasion, and migration abilities of esophageal cancer KYSE150 cells. Upregulation of wild-type FAM166A significantly promoted the malignant phenotype of esophageal cancer cells, while upregulation of the P84L mutant enhanced this effect. An esophageal cancer cell model stably overexpressing wild-type FAM166A and the P84L mutant was constructed, which can serve as a drug screening platform for high-throughput screening of anti-tumor candidate drugs targeting FAM166A or its mutants.

The invention relates to the technical field of biological medicine, in particular to application of a reagent targeting ENO1-PKM interaction in preparation of a medicine for treating HBV-related hepatocellular carcinoma, it is proved that ENO1 and PKM in HBV-related HCC are remarkably overexpressed and directly interact with each other, and ENO1 and PKM synergistically promote HCC cell proliferation, migration and invasion and HBV replication by up-regulating PCNA expression, so that the effect of treating HBV-related hepatocellular carcinoma is achieved. And a glycolysis pathway is activated. Cell experiments and nude mouse transplantation tumor model verification show that the targeting reagent can block ENO1-PKM interaction, down-regulate PCNA expression, inhibit tumor cell malignant phenotypes, reduce HBV DNA replication and HBsAg secretion level, and adjust glycolytic activity. Aiming at the core pathogenic mechanism of HBV-related HCC, the invention provides a novel metabolic treatment strategy with cancer suppression and antiviral effects, and has important clinical application value.

The invention discloses application of FH acetylation in diagnosis, staging, treatment and prognosis prediction of colorectal cancer. According to the application, acetylated non-histone proteins and acetylation sites related to CRC are systematically screened, the regulation effect of the FH K80 acetylation modification level on CRC malignant phenotypes is found for the first time, the FH K80 acetylation modification level shows significant difference in CRC patients and is related to prognosis, and a high acetylation state (FH K80Q) can inhibit CRC cell proliferation, migration and invasion. The application provides a new direction for diagnosis, prognosis prediction and effective treatment of CRC, and has a wide application prospect clinically.